language_icon
EN
HI

Panacea Biotec Share price

PANACEABIO

368.55

12.05 (3.38%)
NSE
BSE
Last updated on 24 Apr, 2026 | 15:55 IST
Today's High

373.00

Today's Low

347.00

52 Week Low

292.40

52 Week High

581.90

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Panacea Biotec Chart

Panacea Biotec Share Key Metrics

Volume
1.77 L
Market Cap
2257.40 CR
LTQ@LTP
3@368.55
ATP
360.12
Var Margin
26.01 %
Circuit Range
285.2-427.8
Delivery %
51.09 %
Value
6.39 CR
ASM/GSM
No
Market Lot
1

Summary

24 Apr, 2026 | 15:55 को, Panacea Biotec का शेयर प्राइस आज ₹368.55 पर है, जो दिन के लिए 12.05% की 3.38 दर्शाता है। स्टॉक की इंट्राडे मूवमेंट ₹347.00 और ₹373.00 के बीच रही है, जबकि 52‑सप्ताह के आधार पर यह ₹292.40 से ₹581.90 तक रही है। ट्रेडिंग गतिविधि के मामले में, Panacea Biotec ने 177387 शेयरों का वॉल्यूम रिकॉर्ड किया है, जिसका मार्केट कैपिटलाइज़ेशन ₹61250746 है। स्टॉक की एवरेज ट्रेडेड प्राइस ₹36012 है, जबकि लास्ट ट्रेडेड क्वांटिटी एट लास्ट ट्रेडेड प्राइस (LTQ@LTP) 3,36855 रही। यह स्टॉक ₹285.2-427.8 की सर्किट रेंज में ट्रेड करता है, और आज का कारोबार मूल्य ₹6.39 CR है। दिन के लिए डिलीवरी परसेंटेज 51.09% रही। इसके अतिरिक्त, Panacea Biotec वर्तमान में No फ्रेमवर्क के तहत आता है और 1 के मार्केट लॉट साइज़ में ट्रेड करता

Panacea Biotec Fundamentals

View More
P/E Ratio

0

P/B Ratio

2.71

Div. Yield

0

Sector P/E

63.82

Sector P/B

3.5

Sec. Div. Yield

0.57

Panacea Biotec Resistance and Support

Pivot 359.35

Resistance

First Resistance

366.4

Second Resistance

376.3

Third Resistance

383.35

Support

First Support

349.45

Second Support

342.4

Third Support

332.5

Panacea Biotec Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

72.48%

Mutual Fund

0%

Insurance

0%

Foreign Institutional Investors

1.6%

Domestic Institutional Investors

1.97%

Retail

23.96%

Others

-0.01%

Total Promoters
MAR '26
72.48%

Panacea Biotec Corporate Actions

DateAgenda
2026-02-11Quarterly Results

Panacea Biotec News

Panacea Biotec Limited

Panacea Biotec Limited secured a ₹20.79 crore order from the Central Medical Services Society (CMSS) for supplying Diphtheria and Tetanus Vaccine (Td Vaccine). The supply will commence in September/October 2026 and conclude by November/December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Limited

Panacea Biotec Limited secured a ₹20.79 crore order from the Central Medical Services Society (CMSS) for supplying Diphtheria and Tetanus Vaccine (Td Vaccine). The supply will commence in September/October 2026 and conclude by November/December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Limited

Panacea Biotec received a Letter of Award worth ₹20.79 crore from the Central Medical Services Society. The contract is for the supply of Diphtheria and Tetanus Vaccine (Td Vaccine) for Adults and Adolescents, to be executed in tranches until November/December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Ltd - 531349 - Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order

Panacea Biotec secured a ₹20.79 crore Letter of Award from Central Medical Services Society (CMSS) for Diphtheria and Tetanus Vaccine supply. This domestic order will be supplied in tranches from October 2026 to December 2028.
Apr 11 2026 16:04:00

Panacea Biotec Ltd - 531349 - Receipt Of Awards From The Presiding Officer Of Industrial Tribunal, Mohali

Panacea Biotec received four awards from an Industrial Tribunal on March 19, 2026, concerning labor disputes with workmen, including back wages and reinstatement. The company plans to appeal the awards and believes there will be no material adverse financial impact.
Apr 10 2026 16:04:00

Panacea Biotec Limited

Panacea Biotec received a rectified DCIT assessment order on April 06, 2026, setting its tax liability for AY 2016-17 as Nil. This action nullifies the previous ~₹10.23 crore demand, correcting errors from the initial order and removing adverse financial impact.
Apr 07 2026 12:04:00

Panacea Biotec Limited

Panacea Biotec's tax liability of ~₹45.71 crore for Assessment Year 2015-16 has been nullified. The Income Tax Department issued a rectified assessment order, correcting errors from the prior demand.
Apr 07 2026 12:04:00

Panacea Biotec Ltd - 531349 - Receipt Of Rectified Assessment Order For AY 2016-17

Panacea Biotec's tax liability for AY 2016-17 has been determined as nil by the DCIT, reversing an earlier demand of ₹10.23 crore. This rectification corrected errors including double disallowances and omission of set-off for brought-forward losses.
Apr 07 2026 11:04:00

Panacea Biotec Ltd - 531349 - Receipt Of Rectified Assessment Order For AY 2015-16

Panacea Biotec's tax liability for Assessment Year 2015-16 has been resolved to Nil following a rectified assessment order from the DCIT. This nullifies the previous demand of ~₹45.71 crore.
Apr 07 2026 11:04:00

Panacea Biotec Limited

Panacea Biotec: Mukul Gupta ceased to be a Non-Executive Independent Director effective March 31, 2026. His cessation is due to the completion of his tenure on the board.
Apr 01 2026 10:04:00
Read More

About Panacea Biotec AboutThe

NSE : 4055  
BSE : 531349  
ISIN : INE922B01023  

Panacea Biotec Ltd. was incorporated as a private limited company in the name and style of Panacea Drugs Private Ltd. on 2nd February 1984. Subsequently the Company became deemed Public limited Company u/s 43A(1 A) of the Companies Act 1956 w.e.f. 30.6.93. The shareholders of the Company in Extra Ordinary General Meeting passed a special resolution on 26.7.93 for deleting the Registration Clause from Articles of Association of the Company u/s 3(1) (iii) of the Companies Act 1956 and as such Company became full fledge public limited Company within the meaning of Section 3 (1) iv) of the Companies Act. Thereafterer the name of the Company hanged to Panacea Biotec Limited on 7th September 1993.The Company has been promoted by Mr. Sosh Kumar Jain who is a pharmacist having about 40 years of experience in the pharmaceutical industry.The Company started its operations in the year 1985 by identifying and importing a group of life saving drugs which were not available in the country for acute diseases like cancer haemophilia cardiac diseases infertility etc. These drugs were imported at an economical price andmade available through a distribution network of stockists all over the country. Having made a significant presence in the markat and after understanding the scope of the product and the latest trend in the medical field the Company made plans to set up its own manufacturing unit in 1989 and thereafter established a marketing team with an already existing distribution network for promotion of ethicalformulations.The promotors of the Company also happened to be the artners in another group company - Radicura Pharma engaged in he line of business of vaccines. Having established its marketing strength in both the group companies i.e. Vaccine Division as well as Pharma marketing the Company decided to make a single entity by merging both the unitsin the year 1992. The company is now utilising the strength of the products and marketing team of both the unit for better performance in the coming years. The Company continue to manufacture the Vaccines under Radicura Pharma with the after now functioning as a division of the Company.The Company started its Export promotion in 1991-92 when product registration in different countries was initiated. During 1993-94 the Comapny exported products worth Rs. 1.00 Crore.Presently the Company is engaged in 4 product lines of Pharmaceuticals. These are :- a) Vaccines b) Biologicals c) formulations d) Natural ProductsThe ethical formulations being promoted is on an all India basis. The Company has a significant presence in different therapeutic Groups. The company has a well established marketing network with dealers spread all over the country. The Company now proposes to expand the capacity of Vaccines Division along with an expansion in the capacities of capsules and suspensions.The company has achieved consistent improvement in rating terms of retail chemist sales out of top 200 Companies in India (Source: ORG Retail Sales Rating) out of companies promoting products ethically.Year March 1993 March 1994Rating 187 153Out of 200 200

Read More

Panacea Biotec Management

NamePosition
Ankit JainCompany Secretary and Compliance Officer
Rajesh JainChairman & Managing Director
View More

Panacea Biotec FAQs

Panacea Biotec शेयर का खरीद मूल्य 368.55 है। लाइव प्राइस और तत्काल ट्रेडिंग के लिए, आप अपने चॉइस ट्रेडिंग खाते में लॉगिन कर सकते हैं या चॉइस के साथ मुक्त डीमैट खाता खोल सकते हैं।

Panacea Biotec शेयर खरीदने के लिए अपने चॉइस ट्रेडिंग खाते में लॉगिन करें, या चॉइस डीमैट खाता खोल, फिर फंड जोड़ें, कंपनी का नाम खोजें, अपना ऑर्डर टाइप चुनें और ट्रेड प्लेस करें।

Panacea Biotec शेयर का प्राइस-टू-अर्निंग्स (पी/ई) रेशियो 0 है। आप सापेक्ष मूल्यांकन के लिए इसकी तुलना सेक्टर के औसत से कर सकते हैं।

Panacea Biotec शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 2.71 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Panacea Biotec शेयर का प्राइस-टू-बुक (पी/बी) रेशियो 3.5 है। यह शेयर के मूल्य की तुलना उसकी बुक वैल्यू से करने में उपयोगी है।

Panacea Biotec का मार्केट कैप 2257.40 CR है। यह कंपनी के आकार की श्रेणी और ट्रेडिंग लिक्विडिटी को दर्शाता है।

Panacea Biotec शेयर का 52 सप्ताह का उच्चतम और न्यूनतम मूल्य 581.90 और 292.40 है। ये मूल्य मूल्य सीमाएं, ट्रेडिंग रेंज, अस्थिरता, संभावित सपोर्ट/रेजिस्टेंस और मूल्य गति को दर्शाते हैं।

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost